Omega-3 Fatty Acids and Health Effects

February 3, 2015 updated by: Stine Marie Ulven, Oslo Metropolitan University
The investigators want to study health effects from omega-3 fatty acids, from fishoil with different quality.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

69

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy individuals.

Exclusion Criteria:

  • Pregnant women, lactating women, chronic diseases and smoking.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: placebo
Dietary supplement: Omega-3
Capsules with omega-3 fatty acids.
Dietary supplement: sun flower oil
Capsules with sun flower oil.
Experimental: omega-3 high quality
Dietary supplement: Omega-3
Capsules with omega-3 fatty acids.
Dietary supplement: sun flower oil
Capsules with sun flower oil.
Experimental: omega-3 low quality
Dietary supplement: Omega-3
Capsules with omega-3 fatty acids.
Dietary supplement: sun flower oil
Capsules with sun flower oil.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Primary and secondary oxidation products
Time Frame: baseline (0 weeks), 3 weeks and 7 weeks
baseline (0 weeks), 3 weeks and 7 weeks

Secondary Outcome Measures

Outcome Measure
Time Frame
inflammatory markers
Time Frame: after 0,3 and 7 weeks
after 0,3 and 7 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oslo Metropolitan University

Investigators

  • Study Chair: Stine M Ulven, PhD, Oslo Metropolitan University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

September 1, 2009

Primary Completion (Actual)

December 1, 2009

Study Completion (Actual)

December 1, 2009

Study Registration Dates

First Submitted

December 16, 2009

First Submitted That Met QC Criteria

December 16, 2009

First Posted (Estimate)

December 17, 2009

Study Record Updates

Last Update Posted (Estimate)

February 4, 2015

Last Update Submitted That Met QC Criteria

February 3, 2015

Last Verified

February 1, 2015

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 6.2008.2215

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Omega-3

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe